RET in Lung Cancer: The Next Big Target?

RET in Lung Cancer: The Next Big Target?

Da: GRACEcast
0 0 5 anni fa
A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

Seguici su Facebook